Clinical trial NCT02458664: BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
Official title: BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rectum Cancer
Cancer of Colon
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2015-06-01
Enrollment: 597
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients, male or female, over 18 years, undergoing curative colorectal resection

Brief summary: We collect prospectively and retrospectively, patients' demographic, pathological, surgical, therapeutic and prognosis informations in a database. After patient's consent to collect tumoural samples of their colorectal cancer after resection.

We will then be able to evaluate the impact of HSP110, a chaperon protein, on their prognosis. Other proteins (to be determined) will also be study, after.

Detailed description: To investigate the importance of HSP110DE9 as a prognostic marker for colorectal cancer, we will analyze genotyping fluorescence quantitative RT-PCR and / or immunomarquage the presence of this mutant in a large cohort of patients (more than 2000 patients had or having a colorectal cancer). All patients have been or will be made in general and digestive surgery department at Saint-Antoine hospital. Tumor fragments samples were or will be made on their tumor and keep it in the tumor bank of the Saint-Antoine hospital. All patients reported their no objection to the use of these tumor fragments for research purposes. A database will be built and correlated with the tumor fragments. This project is intended that the constitution of a clinical database including prognostic so that we make discoveries on HSP110DE9 or other molecular biology to discover markers can be correlated with clinical data. In the absence of other studies on the subject, with no real knowledge of the prognostic impact of this mutant, we cannot provide an effective computation. We therefore propose to make a database of 2000 patients retrospectively and prospectively to obtain statistical results valid and powerful.

Eligibility criteria: Inclusion Criteria:

* All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital.
* Patients reporting their non-opposition to the use of tissue samples taken from their specimen for research purposes.

Exclusion Criteria:

* Patients who did not report their non-opposition to the use of tissue samples taken from their specimen for research purposes.

Primary outcomes:
measure: Recurrence free survival and Recurrence free survival after resection of the colon cancer
timeFrame: End of follow up : at least 3 years
Secondary outcomes:
measure: Overall survival
timeFrame: End of follow up : at least 3 years
Other outcomes:
Locations:
city: Paris
country: France
facility: Department of Digestive Surgery, Hôpital Saint-Antoine
Study officials:
References: